Department of Molecular Oncology


Department head: Ragnhild A. Lothe, Professor
Department administrative consultants: Mona Hagen and Linda Uv Mjøen
Lab manager: Guro E. Lind

Research groups:

GeneticsGenome BiologyEpigenetics

Ragnhild A. LotheRolf I. SkotheimGuro E. Lind

Project group:

Cell signalling


Edward Leithe


Centre for Cancer Biomedicine  

Centre for Cancer Biomedicine

A Norwegian Centre of Excellence funded by the Research Council of Norway.


The K.G. Jebsen Colorectal Cancer Research Centre.




Norwegian Cancer Genomics Consortium


Latest News


Contact information

Department of Molecular Oncology, Institute for Cancer Research
Oslo University Hospital HE - Norwegian Radium Hospital
Mail address: P. O. Box 4953 Nydalen, NO-0424 Oslo, Norway
Street address: Norwegian Radium Hospital, Montebello
Phone: +47 2278 1728, Switchboard: +47 2293 4000, Fax: +47 2278 1745


Three master's students graduated from the Department of Molecular Oncology




From left to right:

MSc Marthe Norreen Thorsen
The title of thesis:  "Functional evaluation of polo like kinase 1 (PLK1), a potential drug target, in malignant peripheral nerve sheath tumor cells"
Supervisors: Matthias Kolberg, Edward Leithe, and Ragnhild A. Lothe

MSc Mariella Evelyn Güere
The title of thesis:  "Identification of DNA methylation biomarkers for gastrointestinal cancer - Ubiquitin C-terminal hydrolase L1 (UCHL1)"
Supervisors: Hege Marie Vedeld and Guro E. Lind

MSc Kristina Totland Carm
The title of thesis:  "Investigation of DNA and RNA changes in multifocal prostate cancer - Identification of novel alterations and molecular subtyping of individual tumors"
Supervisors: Marte Løvf, Rolf Skotheim, and Ragnhild A. Lothe


Epigenetic markers stratify colorectal cancer patients within a genetically defined poor prognostic patient group

Hege Marie Vedeld og Marianne Merok.
Hege Marie Vedeld og Marianne Merok.

Vedeld and co-workers show that the CpG Island Methylator Phenotype (CIMP) carry prognostic value across stages. Patients with microsatellite stable tumors with BRAF V600E mutations, defining a poor prognostic subgroup, can be further subdivided by the CIMP status. This is a study from the Lind and Lothe groups in collaboration with the clinical research team of Arild Nesbakken.